Logo image of CTEV

CLARITEV CORP (CTEV) Stock Fundamental Analysis

NYSE:CTEV - US62548M2098 - Common Stock

61.64 USD
-1.56 (-2.47%)
Last: 9/11/2025, 8:04:01 PM
Fundamental Rating

2

Overall CTEV gets a fundamental rating of 2 out of 10. We evaluated CTEV against 35 industry peers in the Health Care Technology industry. CTEV has a bad profitability rating. Also its financial health evaluation is rather negative. CTEV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year CTEV has reported negative net income.
CTEV had a positive operating cash flow in the past year.
CTEV had negative earnings in 4 of the past 5 years.
In the past 5 years CTEV always reported a positive cash flow from operatings.
CTEV Yearly Net Income VS EBIT VS OCF VS FCFCTEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

The Return On Assets of CTEV (-13.08%) is comparable to the rest of the industry.
CTEV has a better Return On Invested Capital (1.03%) than 68.57% of its industry peers.
CTEV had an Average Return On Invested Capital over the past 3 years of 2.41%. This is below the industry average of 6.80%.
Industry RankSector Rank
ROA -13.08%
ROE N/A
ROIC 1.03%
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
CTEV Yearly ROA, ROE, ROICCTEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

CTEV has a better Operating Margin (6.72%) than 80.00% of its industry peers.
In the last couple of years the Operating Margin of CTEV has declined.
With a decent Gross Margin value of 74.43%, CTEV is doing good in the industry, outperforming 80.00% of the companies in the same industry.
In the last couple of years the Gross Margin of CTEV has declined.
Industry RankSector Rank
OM 6.72%
PM (TTM) N/A
GM 74.43%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
CTEV Yearly Profit, Operating, Gross MarginsCTEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

CTEV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
CTEV has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CTEV has less shares outstanding
The debt/assets ratio for CTEV is higher compared to a year ago.
CTEV Yearly Shares OutstandingCTEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 200M 400M 600M
CTEV Yearly Total Debt VS Total AssetsCTEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.2 Solvency

CTEV has an Altman-Z score of -0.29. This is a bad value and indicates that CTEV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.29, CTEV is in line with its industry, outperforming 45.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.29
ROIC/WACC0.14
WACC7.35%
CTEV Yearly LT Debt VS Equity VS FCFCTEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B 5B

2.3 Liquidity

CTEV has a Current Ratio of 0.98. This is a bad value and indicates that CTEV is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.98, CTEV is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
A Quick Ratio of 0.98 indicates that CTEV may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.98, CTEV is doing worse than 74.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.98
Quick Ratio 0.98
CTEV Yearly Current Assets VS Current LiabilitesCTEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

CTEV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.25%.
Looking at the last year, CTEV shows a decrease in Revenue. The Revenue has decreased by -2.03% in the last year.
CTEV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.09% yearly.
EPS 1Y (TTM)-0.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.3%
Revenue 1Y (TTM)-2.03%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%3.47%

3.2 Future

Based on estimates for the next years, CTEV will show a very strong growth in Earnings Per Share. The EPS will grow by 25.00% on average per year.
CTEV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.88% yearly.
EPS Next Y76.69%
EPS Next 2Y35.39%
EPS Next 3Y25%
EPS Next 5YN/A
Revenue Next Year1.46%
Revenue Next 2Y2.07%
Revenue Next 3Y2.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTEV Yearly Revenue VS EstimatesCTEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
CTEV Yearly EPS VS EstimatesCTEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CTEV. In the last year negative earnings were reported.
Also next year CTEV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEV Price Earnings VS Forward Price EarningsCTEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CTEV is valued cheaply inside the industry as 85.71% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.99
CTEV Per share dataCTEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200

4.3 Compensation for Growth

A more expensive valuation may be justified as CTEV's earnings are expected to grow with 25.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.39%
EPS Next 3Y25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLARITEV CORP

NYSE:CTEV (9/11/2025, 8:04:01 PM)

61.64

-1.56 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)08-06 2025-08-06/bmo
Earnings (Next)11-03 2025-11-03
Inst Owners35.53%
Inst Owner ChangeN/A
Ins Owners8.14%
Ins Owner Change5.51%
Market Cap1.02B
Analysts80
Price Target71.74 (16.39%)
Short Float %9.67%
Short Ratio4.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-10.5%
Min EPS beat(2)-23.58%
Max EPS beat(2)2.57%
EPS beat(4)2
Avg EPS beat(4)-19.98%
Min EPS beat(4)-73.58%
Max EPS beat(4)14.65%
EPS beat(8)5
Avg EPS beat(8)-182.55%
EPS beat(12)6
Avg EPS beat(12)-287.29%
EPS beat(16)8
Avg EPS beat(16)-201.21%
Revenue beat(2)2
Avg Revenue beat(2)2.18%
Min Revenue beat(2)1.86%
Max Revenue beat(2)2.51%
Revenue beat(4)2
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.29%
Max Revenue beat(4)2.51%
Revenue beat(8)2
Avg Revenue beat(8)-2.36%
Revenue beat(12)4
Avg Revenue beat(12)-2.64%
Revenue beat(16)6
Avg Revenue beat(16)-2.02%
PT rev (1m)77.31%
PT rev (3m)224.62%
EPS NQ rev (1m)-5.83%
EPS NQ rev (3m)-54.72%
EPS NY rev (1m)-2.96%
EPS NY rev (3m)-34.31%
Revenue NQ rev (1m)2.02%
Revenue NQ rev (3m)-1.28%
Revenue NY rev (1m)1.3%
Revenue NY rev (3m)1.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.09
P/FCF N/A
P/OCF 14.38
P/B N/A
P/tB N/A
EV/EBITDA 10.99
EPS(TTM)-40.5
EYN/A
EPS(NY)-11.62
Fwd EYN/A
FCF(TTM)-3.34
FCFYN/A
OCF(TTM)4.29
OCFY6.96%
SpS56.8
BVpS-2.42
TBVpS-273.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.08%
ROE N/A
ROCE 1.3%
ROIC 1.03%
ROICexc 1.04%
ROICexgc 16.29%
OM 6.72%
PM (TTM) N/A
GM 74.43%
FCFM N/A
ROA(3y)-13.68%
ROA(5y)-9.22%
ROE(3y)-665.39%
ROE(5y)-402.43%
ROIC(3y)2.41%
ROIC(5y)N/A
ROICexc(3y)2.48%
ROICexc(5y)N/A
ROICexgc(3y)66.67%
ROICexgc(5y)N/A
ROCE(3y)3.05%
ROCE(5y)N/A
ROICexcg growth 3Y-40.96%
ROICexcg growth 5Y-27.14%
ROICexc growth 3Y-26.84%
ROICexc growth 5Y-14.89%
OM growth 3Y-33.57%
OM growth 5Y-22.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.14%
GM growth 5Y-2.61%
F-Score4
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 9.08
Cap/Depr 28.21%
Cap/Sales 13.43%
Interest Coverage 0.23
Cash Conversion 13.9%
Profit Quality N/A
Current Ratio 0.98
Quick Ratio 0.98
Altman-Z -0.29
F-Score4
WACC7.35%
ROIC/WACC0.14
Cap/Depr(3y)24.85%
Cap/Depr(5y)22.67%
Cap/Sales(3y)10.77%
Cap/Sales(5y)9.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%89.3%
EPS Next Y76.69%
EPS Next 2Y35.39%
EPS Next 3Y25%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.03%
Revenue growth 3Y-5.92%
Revenue growth 5Y-1.09%
Sales Q2Q%3.47%
Revenue Next Year1.46%
Revenue Next 2Y2.07%
Revenue Next 3Y2.88%
Revenue Next 5YN/A
EBIT growth 1Y-56%
EBIT growth 3Y-37.5%
EBIT growth 5Y-23.25%
EBIT Next Year144.04%
EBIT Next 3Y35.48%
EBIT Next 5YN/A
FCF growth 1Y-151.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.17%
OCF growth 3Y-35.69%
OCF growth 5Y-17.66%